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Purpose: To evaluate the feasibility and accuracy of dual-energy CT (DECT) 
using multi-material decomposition (MMD) for quantification of the hepatic 
fat fraction (HFF) and to evaluate the diagnostic performance compared with 
the precontrast CT number using the histologic examination as the reference 
standard and MR fat quantification as the technical standard. 
 
Methods: This study was approved by our Institutional Animal Care and Use 
Committee and our Institutional Review Board. In this animal study, various 
degrees of fatty liver were induced in 16 rabbits in four groups, by feeding 
them a high-fat, high-cholesterol diet during 0, two, four, and six weeks, 
respectively. After 6 weeks, precontrast, single-energy CT and multiphasic 
DECT were performed and HFF maps were obtained from the multiphasic 
DECT using MMD. Chemical shift MRI for obtaining the fat fraction map 
and histologic examinations of the liver were also performed. In a human 
study, 14 living liver donors and 11 liver recipients were included and all 
study subjects underwent CT using dual-energy precontrast imaging, chemical 
shift MRI for the fat fraction map, and surgery. The CT attenuation values and 
fat fractions of the DECT, MRI, and pathology results were measured. The 
Pearson’s correlations coefficients were calculated, and Bland-Altman 
analysis was performed among the fat fractions of DECT, MRI, and 
pathology. Receiver operating characteristic (ROC) curve analysis was 





Results: The CT attenuation of precontrast images showed a strongly 
negative linear correlation with the histologic HFF. In the animal study, the 
HFFs of DECT with MMD were strongly correlated with those of pathology 
and MRI, and the mean differences of the Bland-Altman plots comparing the 
fat fractions of multiphasic DECT with MMD were very close to zero, even in 
the presence of iodinated contrast media. However, there was poor agreement 
between the HFF of DECT with MMD and that of pathology. In the human 
study, the HFF of DECT with MMD showed good agreement with those of 
MRI and the pathology results, even though there was no significant linear 
correlation between the HFF of DECT with MMD and that of pathology. The 
diagnostic performance of DECT with MMD regarding sensitivity and 
specificity was comparable to that of precontrast CT and MRI (P = 0.17-0.82). 
 
Conclusions: The quantification of HFF using DECT with MMD is well-
correlated and shows good agreement with the HFF of pathology and MRI 
even in the presence of iodinated contrast media, and has comparable 
sensitivity and specificity to those of precontrast CT and MRI. 
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Hepatic steatosis or fatty liver disease is recognized as the most prevalent 
liver disease worldwide. The prevalence of this disease is rapidly rising along 
with the increasing prevalence of obesity and it is being more frequently 
detected with the increased use of ultrasonography and computed tomography 
(CT). It is known that this condition increases not only the risk of the 
development of liver cirrhosis and hepatocellular carcinoma (1-3), but also the 
risk of mortality after liver resection (4-6). Because the condition can be 
improved with effective treatment and diet, it is very important to know the 
extent of the hepatic steatosis, i.e. the content of fat in liver tissue, so that an 
effective treatment plan can be devised and the treatment results can be 
evaluated. Hepatic steatosis also influences the outcome of liver 
transplantation for both the recipient and the living liver donor during the 
postoperative period (7-9). Severe macrovesicular steatosis (>60%) in donor 
liver has been associated with a greater than 60% risk of primary non-function 
after transplantation, and a moderate degree of macrovesicular steatosis (30-
60%) in donor livers may also result in decreased hepatocyte regeneration and 
higher rates of graft dysfunction, non-function, and ischemic injury (10). 
Therefore, accurate quantification of hepatic steatosis is also critical for the 
selection of living liver donors.  
Histologic examination of hepatocellular fat vacuoles remains the reference 
standard for the detection and quantification of hepatic steatosis, although 




(11). In addition, routine histologic examination is semiquantitative, observer-
dependent, and graded with broad severity brackets (12). Moreover, liver 
biopsy cannot be repeated often enough in order to monitor the treatment 
response due to the procedure-related complications and potential morbidity 
(13). Therefore, an alternative, noninvasive means of diagnosing hepatic 
steatosis would be beneficial. Noninvasive imaging modalities for diagnosing 
fatty liver include ultrasonography, magnetic resonance imaging (MRI), and 
CT. Among these modalities, ultrasonography is the easiest and most widely 
accepted first imaging technique with the additional benefit of its lack of a 
radiation hazard, although it is a subjective method and highly operator- and 
equipment-dependent, so that only a qualitative assessment of the fatty liver is 
possible (14-19). CT depicts focal fatty infiltration of the liver and the diffuse 
fatty liver, as showing low attenuation and the degree of decrease in CT 
attenuation has been shown to be related to the degree of fatty infiltration of 
the liver (20-25). Although CT is useful for the detection of fatty liver, it has 
low sensitivity for detecting mild to moderate hepatic steatosis (26, 27) and 
hemosiderin deposition can preclude an accurate assessment of hepatic 
steatosis based on CT attenuation (28). MR spectroscopy is able to measure 
fat and water proton signals and is probably the best method for detecting a 
small amount of fatty infiltration. As confirmed by biochemical assay of tissue 
specimens, the fat fraction (FF) calculated from proton densities determined 
on spectroscopy is equivalent to the tissue triglyceride concentration (12, 29). 
Recent studies have also demonstrated that low-flip-angle, multiecho, gradient 




T1 independent, T2* corrected chemical shift based fat-water separation with 
multi-peak fat spectral modeling (31) is a rapid, safe, and highly accurate 
diagnostic and fat-grading modality for fatty liver disease. However, MR 
imaging is relatively expensive and limited in its accessibility. 
Meanwhile, recent studies also demonstrated that dual-energy CT which 
involves scanning with two, different tube potentials (typically, 140 and 
80kVp), may be used to evaluate hepatic steatosis by measuring the change in 
hepatic attenuation between images acquired at the lower and higher energy 
levels (25, 32-34). In the situation of hepatic steatosis without iron overload or 
iodinated contrast media, two-material decomposition (MD) with basic 
materials of fat and liver will be able to similarly quantify the degree of 
hepatic steatosis. As multi-material decomposition (MMD) with three basic 
materials of fat, liver, and other, such as iron or iodinated contrast media, 
considers the amount of other material in the liver, it is, therefore, expected 
that MMD will show better performance in quantifying the degree of hepatic 
steatosis in the iron overloaded situation or on post-contrast images than MD. 
MMD is based on the additional assumption of volume conservation (35), 
however, when grinding and mixing of liver tissue, fat, and iron or other 
material, the final volume of the mixed material will change and become 
different with the in-vivo situation. Because the change of total volume of 
mixed materials is thought to affect the amount of calculated fractions of 
decomposed materials, an animal or human study using live tissue is needed to 
evaluate the performance of MMD. If accurate quantification of HFF in 




some patients and the exposed radiation dose from CT scanning could be 
decreased.  
Therefore, the purpose of this study is to evaluate the feasibility and 
accuracy of dual-energy CT (DECT) using multi-material decomposition 
(MMD) for quantification of the hepatic fat fraction (HFF) and to evaluate the 
diagnostic performance compared with the precontrast CT number, using the 
histologic examination as the reference standard and MR fat quantification as 
the technical standard. Quantification of HFF using CT, which is an objective 
imaging modality and is widely used with easy accessibility, would be helpful 
for evaluation of the treatment effect of hepatic steatosis and for preoperative 





1. ANIMAL STUDY  
MATERIALS AND METHODS 
Animal model   
This study was approved by the Institutional Animal Care and Use 
Committee of our medical institution (IACUC No. 12-0068 and 13-0021). 
Sixteen, male, New Zealand White rabbits were randomly divided into four 
groups. As shown in Figure 1, four rabbits (group 1) were fed a standard diet 
for six weeks and were used as the control group. Twelve rabbits (groups 2, 3, 
and 4) were fed a high-fat, high-cholesterol (HFHC) diet (Standard diet + 10% 
lard + 2% cholesterol + 2% maltose dextrin; Dyets, Bethlehem, PA, USA: 
product No. 621079) (36). To reach different stages of fatty liver, four rabbits 
(group 2) were fed a standard diet for four weeks followed by a HFHC diet 
for two weeks, four rabbits (group 3) were fed a standard diet for two weeks 
followed by a HFHC diet for four weeks, and four rabbits (group 4) were fed 
a HFHC diet for six weeks. 
Two animals, one from group 3 and the other from group 4, had suffered 
from anorexia and general weakness, so they did not enough HFHC diet to 
produce hepatic steatosis. Furthermore, the animal in group 4 of the two 
animals died during MRI scanning and, therefore, this case was exempted 
from the fat fraction analysis due to the improper pathologic specimen. All 
animals in group 1, the control group, showed normal liver histology with the 
histologic fat fractions being up to 7%. The animals in group 2 (2 weeks of a 




Figure 1. Diet schedule to produce different stages of hepatic steatosis in 
rabbits of the present study. Group 1 were fed a standard diet for six weeks 
and were used as the control group. Group 4 were fed a high-fat, high-
cholesterol (HFHC) diet (Standard diet + 10% lard + 2% cholesterol + 2% 







(grade 1-2), according to the histologic exam. Groups 3 and 4 (four and six 
weeks of a HFHC diet, respectively) showed histologically moderate to severe 
fatty liver except for the two anorexia cases, and thus ranging from 60% to 
87.5% (grade 2-3). 
 
CT acquisition    
After the six-week feeding period, single- and dual-energy CT imaging 
examinations were performed using a single-source, 64-slice MDCT scanner 
with fast kVp switching technology (Discovery CT750 HD; GE Healthcare). 
The animals were sedated with an intramuscular injection of 5 mg/kg of a 1:1 
combination of tiletamine hydrochloride and zolazepam (Zoletil; Virbac, 
Carros, France) and xylazine hydrochloride (Rompun 2%; Bayer Korea, Seoul, 
Korea). Axial images were obtained with the animals in the supine position, 
and covering the entire liver. The single-energy CT was performed at 120kVp 
and 400mA and the dual-energy CT was performed at two energy levels of 
140kVp, 550 mA and 80kVp, 550 mA. The CT parameters were as follows: 
collimated slice thickness, 5 mm; pitch, 1; and gantry rotation time of 0.5 
seconds. Automatic tube current modulation was not used. 
The multiphasic CT protocol consisted of the precontrast, arterial phase, 
portal-venous phase, and equilibrium phase. The precontrast images were 
obtained using both single- and dual-energy scans. After the precontrast CT 
scans of single- and dual-energy were performed and iodinated contrast 
medium in the amount of 370 mgI/mL (iopromide, Ultravist 370; Bayer 




vein at a rate of 1.2 ml/s for five seconds using a power injector (Stellant Dual; 
Medrad, Indianola, PA, USA). Equilibrium-phase images were obtained with 
single-tube energy of 120kVp, whereas arterial and portal venous phase 
images were obtained with dual-energy scans. The arterial, portal-venous, and 
equilibrium-phase scans were obtained 10 seconds, 20 seconds, and 60 
seconds, respectively, after the start of contrast-medium administration. 
 
Postprocessing of DECT  
After CT data acquisition, the DECT data were used for MD and MMD fat 
fraction map reconstruction, and material specific images were obtained on a 
separate workstation (GSI Viewer; GE Healthcare). MD was performed using 
projection-based methods (37) with fat and soft tissue in the material basis. 
The MD output consisted of a basic pair of fat and soft-tissue density images. 
The MMD algorithm used in this study was a liver-fat quantification (LFQ) 
algorithm using commercially unavailable postprocessing software (Liver Fat 
Quantification; GE Healthcare). An LFQ algorithm was recently developed 
using the MMD-based algorithm for direct and accurate liver fat 
quantification using DECT, with fat, liver tissue, and blood in the material 
basis (37). For three-material decomposition using only two, different spectral 
data, one additional condition must be provided to solve for three unknowns. 
It is an ideal solution assumption that the sum of the volume of the three, 
constituent materials equals the volume of the mixture (35, 38, 39). In the case 
of contrast-enhanced DECT data, a virtual unenhancement (VUE) image in 




replaced by the same volume of blood, was first applied before running the 




After the CT scan, MR imaging examinations were performed on a 3T MR 
imaging system (Magnetom Trio, Siemens Medical Solutions, Erlangen, 
Germany) using a human knee coil and a 1.5T MR imaging system 
(SignaHDxt, GE Medical Systems, Milwaukee, WI, USA) using a human 
cardiac coil on the same day as the CT scan. A bandage for pressing on the 
abdomen of the animals was used in order to reduce respiratory motion 
artifacts. A T1-weighted, in-phase and opposed-phase (IOP), spoiled gradient 
recalled echo sequence was performed on a 3T MR system in the axial plane 
using the following imaging parameters: repetition time (TR) 6.5 msec; echo 
times (TE) opposed-phase 2.4 msec; TE in-phase 4.0 msec; echo-train length 
(ETL) 1; ip angle (FA) 9°; number of excitations (NEX) 10; slice thickness 
3.2 mm; matrix 320 x 288; and eld of view (FOV) 140 mm. In addition, the 
iterative decomposition of water and fat using echo-asymmetry and the least-
squares estimation quantitative sequence (IDEAL IQ, GE Healthcare) were 
obtained to estimate the HFF on a 1.5T MR system in the axial plane using 
the following imaging parameters: TR 16.2 msec; rst TE 1.8 msec; echo 
spacing 2.1 msec; ETL 6; FA 8°; NEX 2; slice thickness 2 mm; matrix 256 x 
160; and FOV 230 mm. IDEAL IQ produced T2*-corrected water, T2*-





Image analysis of CT and MR Imaging 
CT imaging - To measure the Hounsfield units (HU) of the CT image 
series, three circular regions of interests (ROI), 30-40 mm2 in size, were 
placed on the liver parenchyma of the 70keV DECT portal venous phase 
image by one blinded radiologist (B.Y.H), taking care to avoid large hepatic 
vessels and artifacts, i.e. one in the right lobe, one in the left medial lobe, and 
one in the left lateral lobe, using the gallbladder and left hepatic vein as 
anatomical landmarks. The ROIs were then copied from the 70keV DECT 
portal venous phase image and pasted onto the other CT image series, i.e. the 
precontrast and equilibrium phase with single-energy and the precontrast, 
arterial phase, and equilibrium phase with dual-energy. The mean HU of the 
CT image series was recorded. To estimate the HFF from MD, 3D ROI 
measurement was performed on the MD fat maps (soft tissue) and the MD 
soft- tissue maps (fat). 2D ROIs were manually drawn on all slices containing 
the liver using ITK-SNAP version 2.2.0 (40). The voxels corresponding to 
these ROIs were combined to form a 3D ROI, and the mean was calculated 
from these voxels. Fat fractions of MD were calculated using the following 
formula: (value of fat density image) / (value of fat density image + value of 
soft tissue density image) (37). HFF of MMD was also measured by 3D ROI 
measurement method, as described above.  
MR Imaging - On MR images, ROIs were defined on the in-phase image 
series in the manner used in measuring the HU of CT images, and was then 




and the IDEAL T2*-corrected fat-fraction images. Signal intensity (SI) 
decrease on opposed-phase images compared with in-phase images was 
calculated using the following formula: SIin−SIout/2ⅹSIin (19), and ROI 
measurements of the HFF on the IDEAL fat-fraction images were recorded. 
The average of the three ROI measurements for each series of MR imaging 
was used as a representative value. 
 
Histologic analysis  
After the MRI exam, all animals were sacrificed by intravenous injection of 
3 mL of KCl under deep anesthesia. The liver tissue specimens were obtained 
from four parts of the liver, i.e. right posterior, right anterior, left medial, and 
left lateral segments. All tissue specimens were fixed in 10% formalin for 48 
hours, embedded in paraffin, cut into 5-um thick slices, and stained with 
Hematoxylin and Eosin (H&E). The degree of fat accumulation was reviewed 
in H&E-stained preparations by one blinded pathologist (K.B.L, 11 years of 
clinical experience conducting hepatic pathologic examinations). As fat 
accumulation was observed as vacuoles in hepatocytes in these preparations, 
the degree of fat accumulation was quantitatively assessed by the degree of 
vacuolation using the percentage of volume of fat vacuoles over the total 
volume of hepatocytes. The degree of fat accumulation was also classified 
into four, semi-quantitative groups: normal being less than 5%; mild between 
5% and 33%; moderate between 33% and 66%; and severe with more than 66% 
of fat vacuoles within the cytoplasm of the hepatocytes, according to the 






The one-way analysis of variance (ANOVA) test was used for the 
intergroup comparison of the CT Hounsfield unit data and the HFF analysis 
among the four animal groups. When statistically significant differences 
occurred, single post-test comparisons were performed using the Tukey post-
hoc comparison tests with Bonferroni correction for multiple comparisons. 
The Pearson correlation coefficient and the paired t test were used for 
statistical analysis to determine the correlation between the HFFs of 
multiphasic DECT data, MRI with IDEAL IQ and IOP, and pathologic 
steatosis. Bland–Altman analysis was also used to determine the agreement 
among the HFFs of DECT, MRI IDEAL IQ, and the pathology results. In 
addition, receiver operating characteristic (ROC) curve analysis was 
performed to evaluate the diagnostic performance and to determine the 
optimal cutoff values of the CT attenuation value of precontrast SECT, HFFs 
of DECT with MMD, and MRI IDEAL IQ, for identifying the presence of 
hepatic steatosis or substantial steatosis. Substantial steatosis was defined as 
>10% steatosis as this criterion was considered as requiring further evaluation 
or dietary intervention before liver donation. The optimal cutoff value was 
defined as the value at which the sum of the sensitivity and specificity was 
maximized. All statistical analyses were performed using commercially 
available software (SPSS, version 21.0; SPSS, Chicago, IL, USA). A P value 





1. ANIMAL STUDY 
RESULTS 
CT attenuation coefficients  
As expected, there were significant differences regarding the CT 
attenuation values of the precontrast images among the four groups (P = 
<0.001 for SECT; P = 0.002 for DECT), while there was no significant 
difference among the four groups in terms of the CT attenuation values of all 
of the post-contrast image sets (P = 0.231-0.997). When comparing the CT 
values of the precontrast image sets, i.e. 120kVp image of SECT and 70keV 
image of DECT, there was no significant difference (P = 0.163).  
The CT attenuation values of the precontrast images showed a strongly 
negative linear correlation with the histologic HFF (r = -0.868 and P < 0.001 
for SECT; r = -0.889 and P < 0.001 for DECT). On the other hand, there was 
no significant correlation between the CT value of the post-contrast image sets 
and the histologic HFF (P = 0.234-0.365). 
 
Correlation of measured HFFs of DECT and MRI with pathology 
Table 1 shows the measured HFF values of pathology, multiphasic DECT, 
and MRI for each animal. The HFF results using MD of post-contrast DECT 
data were negative values which could not have actually occurred. Therefore, 
we did not consider the MD results of post-contrast DECT in Table 1 and the 

























101 0 <5 1.0 0.7 1.1 0.7 13.2 3 6.7 
102 0 <5 1.5 1.6 1.7 2 14.6 3 3.8 
103 0 6.0 2.2 2.7 1.9 2 16.1 3 5.6 
104 0 7.0 0.5 0.6 0.2 0.5 17.3 2 3.4 
201 2 25.0 6.7 6.5 6.2 6.6 21.3 9 9.5 
202 2 32.5 6.7 7.0 4.7 6.4 22.9 8 8.2 
203 2 35.0 6.4 5.4 4.0 6.1 23.0 8 11.8 
204 2 20.0 8.6 7.2 6.4 6.3 21.3 9 6.8 
301 4 68.3 15.6 15.3 14.2 14.7 32.2 15 16.5 
302 4 60.0 20.9 20.4 18.4 19.4 23.1 8 8.85 
303 4 5.0 12.6 11.3 13.8 14.6 15.4 5 3.2 




401 6 72.5 12.4 13.1 10.4 11.8 30.1 9 10.3 
402 6 87.5 20.6 19.4 15.9 17.3 32.2 11 8.4 
403 6 67.5 19.5 17.8 16.3 16.4 21.1 7 61. 
404 6 - 17.1 16.7 15.2 15.4 19.5 5 3.1 
Note.— MMD = multi-material decomposition, MD = material decomposition, DECT = dual-energy CT, AP = arterial phase, 
PVP = portal venous phase, EP = equilibrium phase, IDEAL = iterative decomposition of water and fat using echo-asymmetry and 





The HFF using MMD of precontrast DECT was significantly higher than 
that of the post-contrast DECT image sets which were obtained in the arterial, 
portal venous, and equilibrium phases (P < 0.05). However, the mean 
differences of the Bland-Altman plots comparing the MMD fat fractions of 
precontrast and post-contrast DECT data were -0.6% in the arterial phase, -1.5% 
in the portal venous phase, and -0.9% in the equilibrium phase, and which 
were close to zero, as shown in Figure 2.   
The HFFs measured by multiphasic DECT using either MMD or MD, were 
strongly correlated with the histologic HFF (P <0.001). The correlation 
coefficients of the MMD fat fraction results of the four phases were similar to 
each other (r = 0.854 of precontrast, r = 0.874 of the arterial phase, r = 0.794 
of the portal-venous phase, and r = 0.813 of the equilibrium phase; P < 0.001 
of all phases), and the correlation coefficient of the MD fat fraction of 
precontrast DECT showed the highest value (r = 0.929, P < 0.001). The 
measured HFFs of multiphasic DECT with MMD were also strongly 
correlated with that of MR IDEAL IQ (r = 0.652 - 0.896, P < 0.01), whereas 
there was no significant correlation between the HFFs of multiphasic DECT 
and MR IOP (P = 0.082-0.132). The HFFs measured by IDEAL IQ and IOP 
were strongly correlated with that of pathology (r = 0.834 of IDEAL IQ, r = 
0.716 of IOP; P < 0.001). Figure 3 shows the scatter charts of HFFs of 
precontrast DECT with MMD, MR IDEAL IQ, and pathology. The linear 
regression equations were obtained of these measured HFFs. The equation of 
the HFFs of precontrast DECT with MMD (X) and HFFs of pathology (Y) 




Figure 2. Bland-Altman plots of the fat fractions (%) of DECT with MMD of 
pre- and AP (a), pre- and PVP (b), and pre- and EP (c). pre = precontrast, AP 
= arterial phase, PVP = portal venous phase, EP = equilibrium phase. These 
results indicate good agreement among the MMD fat fractions of multiphasic 




















Figure 3. Correlation of the hepatic fat fraction values between (a) precontrast 
DECT with MMD and MR IDEAL IQ, (b) precontrast DECT with MMD and 
pathology, and (c) MR IDEAL IQ and pathology. There are strong 




































The Bland-Altman plots comparing the HFFs of MMD of precontrast 
DECT and MR IDEAL IQ showed a mean difference of 3.1%, which did not 
differ significantly from zero, while comparison of the fat fractions of MMD 
of precontrast DECT and pathology was -28.4%, thus indicating poor 
agreement between the two measurements. The Bland-Altman plot comparing 
HFFs of MR IDEAL IQ and pathology also showed a mean difference of -
31.5%, similar to the mean difference of the Bland-Altman plot comparing the 
HFFs of DECT with MMD and pathology (Figure 4).  
The CT and MRI of representative subjects in groups 1 and 4 are shown in 





Figure 4. In the animal study, Bland-Altman plots of the fat fractions (%) of 
DECT with MMD and MR IDEAL (a), the fat fractions of DECT with MMD 
and the pathology results, and the fat fractions of MR IDEAL and pathology 
results (c). These results indicate that the fat fraction of DECT MMD is 
comparable with that of MR IDEAL for the quantitative estimation of hepatic 
steatosis, however, the fat fraction of DECT MMD and MR IDEAL differ 


















Figure 5. Representative case in group 1 of the animal study, in which the 
animals were fed a standard diet for six weeks as the control group. (a) 
precontrast, single-energy CT image, (b) fat fraction maps from IDEAL IQ, (c) 
MMD fat fraction map of precontrast DECT, and (d) MMD fat fraction map 
of portal phase DECT. The hepatic HU of (a) was 60.0 and the measured fat 
fractions of (b-d) were 3.0, 2.2, and 1.9 respectively. (e) Gross specimen of 
the liver and (f) high-power photomicrograph with hematoxylin-eosin stain. 




































Figure 6. Representative case in group 4 of the animal study, and which was 
fed a high-fat, high-cholesterol diet for six weeks. (a) precontrast single-
energy CT image, (b) fat fraction maps from IDEAL IQ, (c) MMD fat fraction 
map of precontrast DECT, and (d) MMD fat fraction map of portal phase 
DECT. The hepatic HU of (a) was 31.5 and the measured fat fractions of (b-d) 
were 11.0, 20.6, and 15.9 respectively. (e) Gross specimen of the liver and (f) 
high-power photomicrograph with hematoxylin-eosin stain. Diffuse severe 







































Diagnostic Performance of DECT with MMD for detecting hepatic 
steatosis 
When the cutoff value for the CT number of precontrast SECT was set at 60 
HU for the diagnosis of more than 5% hepatic steatosis, the area under the 
ROC curve was 0.962 (95% CI, 0.721-1.000) with a sensitivity of 92.3% and 
specificity of 100%. And when the cutoff value of HFF for the diagnosis of 
more than 5% hepatic steatosis was set at 1.5% for DECT with MMD and at 3% 
for MR IDEAL IQ, the areas under the ROC curves were 0.923 (95% CI, 
0.667-0.997) and 0.885 (95% CI, 0.617-0.989), respectively. The DECT with 
MMD showed 92.3% sensitivity and 100% specificity, and MR IDEAL IQ 
showed 84.6% sensitivity and 10% specificity for detecting more than 5% 
hepatic steatosis. The DECT with MMD showed the same sensitivity as that 
of the precontrast SECT. Although the DECT with MMD provided higher 
sensitivity than MR IDEAL IQ for detecting more than 5% hepatic steatosis, 
there was no statistical difference of the area under the ROC curves between 
the methods (P = 0.317). For the diagnosis of more than 10% hepatic steatosis, 
the cutoff values were set at 52.5 HU for precontrast SECT, 2.2% for the fat 
fraction of DECT with MMD, and 5% for the fat fraction of MR IDEAL IQ. 
The sensitivities and specificities are 90% and 100% for precontrast SECT 
and and 100% and 80% for the fat fraction of DECT with MMD and MR 
IDEAL, respectively. The diagnostic performance of DECT with MMD for 
more than 10% hepatic steatosis was the same with that of MR IDEAL IQ. 
Table 2 shows the summary of the diagnostic performance and the cutoff 




Table 2. Summary of the diagnostic performance and cutoff values of the CT number of SECT, and the fat fractions of DECT with MMD and 
MR IDEAL for detecting more than 5% or 10% hepatic steatosis, in the animal study.  
 Modality AUROC Criterion Sensitivity Specificity 
≥5% hepatic 
steatosis 
SECT 0.962 (0.721 - 1.000) 60 92.3% 100% 
DECT with MMD 0.923 (0.667 - 0.997) 1.5 92.3% 100% 
MR IDEAL 0.885 (0.617 - 0.989) 3 84.6% 100% 
≥10% hepatic 
steatosis 
SECT 0.980 (0.749 - 1.000) 52.5 90.0% 100% 
DECT with MMD 0.900 (0.637 - 0.993) 2.2 100% 80% 
MR IDEAL 1.000 (0.782 - 1.000) 5 100% 80% 
Note – Number in parentheses are the 95% confidence interval values; SECT = single-energy CT, DECT = dual-energy CT, MMD = multi-
material decomposition, IDEAL = iterative decomposition of water and fat using echo-asymmetry and the least-squares estimation 





2. HUMAN STUDY 
MATERIALS AND METHODS 
Patients    
This study was approved by our Institutional Review Board (IRB No. H-
1202-086-398). From November 2012 to July 2013, 27 potential liver donors 
and 18 potential liver recipients were included in this study and had 
undergone liver CT according to the liver donor protocol and liver recipient 
protocol, respectively. Of these 45 patients, 20 were excluded from the study 
because they did not undergo MR imaging or surgery due to various causes 
including 1) anatomical variation of the hepatic vessels or bile duct or the 
presence of another donor with more suitable anatomy (n = 13), 2) dual 
energy CT data were not available (n = 4) or 3) economic problems (n = 3). 
Finally, 14 living liver donors (seven males and seven females; mean age, 
32.9 years; age range, 20-51 years) and 11 liver recipients (seven males and 
four females; mean age, 53.7 years; age range, 42-65 years) were included in 
our study. All subjects underwent CT with dual-energy precontrast imaging, 
MRI, and hepatectomy surgery for liver recipients and right hemihepatectomy 
for liver donors. 
 
CT acquisition 
All patients underwent multiphasic liver CT using a single-source, 64-slice 
MDCT scanner with a fast kVp switching technology (Discovery CT750 HD; 




early arterial phase, portal venous phase, and equilibrium phases. The 
precontrast images were obtained using a dual-energy protocol at two energy 
levels of 140kVp and 80kVp with 375 mA and 5–mm, collimated slice 
thickness. The arterial, portal-venous, and equilibrium phases were obtained 
using a single-energy protocol at 120kVp with 350 mA and 1.25-mm 
collimated slice thickness. The other CT parameters were as follows: pitch, 1; 
gantry rotation time of 0.5 seconds; and noise index, 15. The automated tube 
current modulation (ATCM, Auto mA 3D; GE Healthcare) program was used.  
After the precontrast CT scanning was performed, iodinated contrast 
medium in the amount of 370 mgI/mL (iopromide, Ultravist 370; Bayer 
Schering, Berlin, Germany) at a dose of 1.5 mL/kg (555 mgI/kg) per body 
weight, was injected for 30 seconds using a power injector (Stellant Dual; 
Medrad, Indianola, PA, USA) and was followed by an injection of 30-40 mL 
of normal saline. The timing for the arterial phase scanning was determined 
using the bolus tracking technique; i.e. arterial-phase scanning was 
automatically started after five seconds for the donor protocol and after 17 
seconds for the recipient protocol after the attenuation coefficient of the 
abdominal aortic blood reached 100 HU at 120kVp. Portal-venous phase and 
equilibrium-phase scanning were obtained 45 seconds and 2-3 minutes, 
respectively, after the start of contrast-medium administration. Arterial, portal, 
and equilibrium-phase images were part of the CT protocol, although they 
were not analyzed in this study. 
The LFQ algorithm was used to obtain the HFF map from precontrast 





MR imaging acquisition  
MR imaging examinations for 14 living liver donors were performed on a 
3T MR imaging system (Magnetom Verio, Siemens Medical Solutions, 
Erlangen, Germany) using a 32-channel, phase-array torso coil and a 1.5T MR 
imaging system (SignaHDxt, GE Medical Systems, Milwaukee, WI, USA) 
using an 8-channel, torso phased-array coil. The IDEAL IQ was obtained for 
the fat fraction map acquisition on the 1.5T MR system in the axial plane 
using the following imaging parameters: TR 12.3 msec; rst TE 0.9 msec; 
echo spacing 1.8 msec; ETL 6; FA 7°; NEX 2; slice thickness 6 mm; matrix 
256 x 160; and FOV 350 mm. IDEAL IQ produced T2*-corrected water, T2*-
corrected fat, R2* maps, and fat-fraction maps. The 11 liver recipients 
underwent MR imaging on a 1.5T MR imaging system (SignaHDxt, GE 
Medical Systems, Milwaukee, WI, USA) using an 8-channel, torso phased-
array coil. The IDEAL IQ was obtained as described above. The mean time 
interval between CT imaging and MR imaging was 10 days with a range of 0-
50 days.  
 
Image analysis   
To estimate the HFF, ROI measurement was performed by one blinded 
radiologist (B.Y.H). Hepatic ROIs were chosen so as to be approximately 200 
mm2 in size and avoiding visible blood vessels, focal hepatic lesions, and 
artifacts. On each image series, 15 ROI measurements (three ROIs per slice x 




were placed on the 70keV precontrast image and the ROI positions were kept 
constant on the MMD fat map of DECT by applying a copy-and-paste 
function at the workstation. The HUs of the 70keV precontrast image and the 
ROI values of the fat map were recorded. The estimated histologic fat fraction 
was also calculated using the equation of the HFFs using the MMD of 
precontrast DECT (X) and the fat fraction of pathology (Y), which was 
suggested in the aforementioned animal experiment: Y = 3.62X + 1. On MR 
images, ROIs were defined on the IDEAL T2*-corrected fat-fraction images 
in the manner used for measuring the HU of CT images, and the ROI values 
of the fat-fraction map were recorded. The average of the ROI measurements 
for each series was used as a representative value, and the fat fractions 
obtained from CT and MR imaging were converted into four, semiquantitative 
classifications according to the steatosis score of the NAS system. 
 
Histologic analysis  
The mean of the time interval between CT imaging and surgery was 28.7 
days (range, 1-93 days) and that between MR imaging and surgery was 21.9 
days (range, 2-93 days). The surgical hepatic specimens were taken from the 
right hepatic lobe, and all specimens were stained with H&E. The blinded 
pathologists reviewed the pathology slides to evaluate the degree of steatosis, 
and that pathologic report was retrospectively reviewed. The degree of 
macrovesicular and microvesicular steatosis was subjectively and 
quantitatively assessed using the percentage of hepatocytes containing 




steatosis was also classified into four, semi-quantitative groups, with normal 
being less than 5%, mild between 5% and 33%, moderate between 33% and 
66%, and severe with more than 66% of the hepatocytes having fat vacuoles 
within the cytoplasm, according to the steatosis score of the NAS system. 
 
Statistical analysis 
To determine the correlation between the HFFs of DECT, MRI IDEAL, 
and pathologic steatosis, the Pearson correlation coefficient was used for 
statistical analysis. The cross-correlation analysis and chi-square test were 
used for correlation analysis between the hepatic steatosis classifications of 
DECT, MRI IDEAL, and pathology. Bland–Altman analysis was also used to 
determine the agreement among the HFFs of DECT, MRI IDEAL, and the 
pathology results. As in the animal experiment, ROC curve analysis was 
performed to evaluate the diagnostic performance and to determine the 
optimal cutoff values of the CT attenuation value of precontrast SECT, HFFs 
of DECT with MMD, and MRI IDEAL IQ for identifying the presence of 
hepatic steatosis or substantial (≥ 10%) steatosis. The optimal cutoff value 
was defined as the value at which the sum of the sensitivity and specificity 
was maximized. All statistical analyses were performed using commercially 
available software (SPSS, version 21.0; SPSS, Chicago, IL, USA). A P value 




2. HUMAN STUDY 
RESULTS 
Histopathologic results of hepatic steatosis  
In the liver donor group, the hepatic steatosis scores of 11 donors were 
normal and those of the other three donors were of a mild degree. Among the 
three liver donors with mild hepatic steatosis, one showed 5% HFF in the 
pathology results and also 5% HFF of MR IDEAL IQ. Another liver donor 
with mild hepatic steatosis had undergone liver biopsy because 13.7% of HFF 
was suggested on preoperative MR IDEAL IQ, and 10% of histologic HFF 
was confirmed by the liver biopsy. This liver donor went on a diet and 
exercised for about two weeks so that the final pathologic fat fraction of the 
surgical specimen was less than 5%. The fat fraction of the last remaining 
liver donor with mild hepatic steatosis was underestimated preoperatively as 
4.2%, while the final pathologic fat fraction was 20% (5% macrovesicular 
fatty change of the total volume of hepatic parenchyme and 15% 
microvesicular fatty change of the total number of hepatocytes). In the liver 
recipient group, there were six with no fatty change, three with a mild degree, 
and two with a moderate degree of hepatic steatosis, while there was no 
moderate degree of hepatic steatosis in the preoperative imaging study. 
Overall, according to the pathologic steatosis score, there were 17 with 
normal liver, six with a mild degree, and two with a moderate degree of 





Correlation between HFFs of DECT with MMD and MR with 
pathology 
The CT attenuation value of the 70keV precontrast image of DECT showed 
a negative linear correlation with the histologic HFF (r = -0.427 and P = 
0.033). However, there was no significant linear correlation between the HFF 
of DECT with MMD and that of histology (P = 0.082), and also between the 
equation-based estimated HFF of DECT with MMD and the histologic HFF 
(P = 0.082). The fat fraction of MR IDEAL IQ showed a positive correlation 
with that of DECT with MMD (r = 0.483 and P = 0.014) and that of histology 
(r = 0.525 and P = 0.007). In the cross-correlation analysis regarding the 
steatosis score of the NAS system, DECT with MMD showed no significant 
correlation with the histologic result (P = 0.206) and MR IDEAL IQ (P = 
0.070), although there was a significant correlation between the equation-
based estimated fat fraction of DECT with MMD and the fat fraction of 
histology (P = 0.014) and MR IDEAL IQ (P = 0.027). 
Figure 7 shows the Bland-Altman plots between the HFFs of DECT, MRI, 
and pathology. The Bland-Altman plot comparing the fat fraction of DECT 
with MMD and that of MR IDEAL IQ showed a mean difference of 0.7%, 
and comparison of the fat fraction of DECT with MMD and the histologic fat 
fraction showed a mean difference of -3.0%, which indicated good agreement 
of the MMD fat fraction of DECT with histologic examination as a reference 
standard and MR fat quantification as a technical standard. The 95% Bland-
Altman limits of agreement between the DECT using the MMD fat fraction 




Figure 7. In the human study, Bland-Altman plots of the fat fractions (%) of 
MDCT with MMD and MR IDEAL (a), the fat fractions of MDCT with 
MMD and the pathology results, and the fat fractions of MR IDEAL and the 
pathology results (c). Note that the high accuracy of the MDCT MMD fat 
fraction for the quantitative estimation of hepatic steatosis, compared with 
histologic examination as the reference standard and MR fat quantification as 


















23.8% for the histologic examination and -5.7% to 7.1% for the MR IDEAL 
technique, and thus indicating the high accuracy of DECT using MMD for 
quantitatively estimating hepatic steatosis. Also, the Bland-Altman plot 
comparing the fat fraction of MR IDEAL IQ and that of histologic 
examination showed a mean difference of -3.7% with the 95% Bland-Altman 
limits of agreement of -23.5% to 16.1%, which does not differ from the 
Bland-Altman plot comparing the fat fraction of DECT using MMD and that 
of pathology. However, the mean difference of the Bland-Altman plot 
comparing the equation-based, estimated fat fraction of DECT with MMD 
and the histologic fat fraction, was 10.0% (not shown in Figure 7), which 
showed poorer agreement than did the measured fat fraction of DECT with 
MMD.  
 
Diagnostic Performance of DECT with MMD for detection of 
hepatic steatosis  
 Table 3 shows the summary of the diagnostic performance and cutoff 
values of the ROC analysis in the human study. For detecting more than 5% 
hepatic steatosis, the cutoff values were set at 50.0 HU for the precontrast 
SECT, 3.5% for the fat fraction of DECT with MMD, and 4% for the fat 
fraction of MR IDEAL IQ. The sensitivities and specificities were 75% and 
70.6% for the precontrast SECT, 87.5% and 64.7% for the fat fraction of 
DECT with MMD, and 62.5% and 88.2% for MR IDEAL, respectively. When 
the cutoff value for precontrast SECT to diagnose more than 10% hepatic 




The cutoff value for DECT with MMD was also 3.5% for detecting more than 
10% hepatic steatosis with 83.3% sensitivity and 57.9% specificity. DECT 
with MMD showed a much higher sensitivity than SECT with lower 
specificity. Regarding the MR IDEAL IQ, when the cutoff value for diagnosis 
of more than 10% hepatic steatosis was set at 4%, the sensitivity was 66.7% 
and the specificity was 84.2%. Although the DECT with MMD provided 
higher sensitivity than MR IDEAL IQ and the MR IDEAL IQ showed higher 
specificity than DECT with MMD for detecting more than 5% or 10% hepatic 
steatosis, there was no statistical difference of the area under the ROC curves 






Table 3. Summary of the diagnostic performance and cutoff values of the CT number of SECT, and the fat fractions of DECT with MMD and 
MR IDEAL for detecting more than 5% or 10% hepatic steatosis, in the human study.  
 Modality AUROC Criterion Sensitivity Specificity 
≥5% hepatic 
steatosis 
SECT 0.706 (0.491 - 0.869) 50.0 75.0% 70.6% 
DECT with MMD 0.721 (0.507 - 0.880) 3.5 87.5% 64.7% 
MR IDEAL 0.772 (0.562 - 0.914) 4 62.5% 88.2% 
≥10% hepatic 
steatosis 
SECT 0.632 (0.417 - 0.814) 44.7 33.3% 100% 
DECT with MMD 0.632 (0.417 - 0.814) 3.5 83.3% 57.9% 
MR IDEAL 0.816 (0.611 - 0.941) 4 66.7% 84.2% 
Note – Number in parentheses are the 95% confidence interval values; SECT = single-energy CT, DECT = dual-energy CT, MMD = multi-
material decomposition, IDEAL = iterative decomposition of water and fat using echo-asymmetry and the least-squares estimation 







The animal study results demonstrated that the HFFs of DECT with MMD 
were well-correlated with those of pathology and MRI, and provided 
consistent fat-fraction results even in the presence of iodinated contrast media. 
However, in the human study, HFF of DECT with MMD showed good 
agreement with the MRI and pathology results. The ROC analysis in the 
animal study also showed DECT with MMD to have comparable diagnostic 
performance with that of the precontrast SECT and MRI, for detecting more 
than 5% hepatic steatosis. In this human study, DECT with MMD showed 
relatively higher sensitivity and lower specificity than did precontrast SECT 
and MRI, however, the overall diagnostic performance was similar between 
the methods.  
Until now, there have been controversial reports regarding the value of 
DECT for hepatic fat quantification. Some previous reports have suggested 
that DECT have showed promise for the identification of various soft-tissue 
types, calcified structures, and iodinated contrast media (42, 43), and that 
DECT was able to accurately predict the liver fat content in an animal study 
(25). The value of DECT for fat quantification could be attributed to the fact 
that the DECT data permits distinguishing materials with comparable atomic 
numbers due to differences in the photoelectric effect and Compton scatter on 
CT attenuation at different photon energies (35, 44-46). However, other 
reports maintain that dual-energy images generated using different ratios of 




the liver in the presence of hemochromatosis or hemosiderosis (26, 32, 47). 
Based on this animal study results which demonstrated that the quantification 
of HFF using DECT with MMD is strongly correlated with the histologic fat 
fraction even in the presence of iodinated contrast media, it is expected that 
the precontrast scan would be omitted in some patients so that the radiation 
dose from CT scanning, which has become one of the major recent concerns, 
could be decreased.  
In the present study, the hepatic attenuation coefficients on precontrast 
SECT or DECT showed a negative correlation with the pathologic HFF. 
However, although the degree of hepatic steatosis can be estimated by 
measuring the hepatic attenuation coefficient (22, 24, 48, 49), there are some 
limitations in the quantification of HFF using SECT. First, there were 
different CT attenuation values when CT scanning was performed at different 
energy levels in the same liver (49). The CT attenuation value was changed 
according to the influence of equipment, scanning qualification, etc. (25, 32). 
However, the tendency toward a negative linear correlation between the CT 
attenuation value and the histologic fat fraction was assured in this study. In 
addition, in the presence of iron or iodinated contrast media, quantification of 
HFF is not possible with SECT (48). Both iron and iodinated contrast media 
confound measurements by an increase in attenuation with higher iron or 
iodine concentrations, i.e. an inverse effect to fat (32, 50). This problem is one 
of the clinical issues because iron sometimes co-exists with fat infiltration in 
chronic liver disease. Moreover, quantification of HFF is also desirable in 




determine whether DECT with MMD could demonstrate an acceptable range 
of diagnostic accuracy for estimating HFF in the presence of both hepatic iron 
deposition and hepatic steatosis.  
Interestingly, in the animal experiment, although the HFF values of DECT 
with MMD were well-correlated with the histologic fat fraction, the absolute 
values of the fat fraction from DECT and pathology differed and showed poor 
agreement. The histologic fat fraction in the animal experiment was 
approximately three to four times larger than that of DECT with MMD (P = 
0.001). On the other hand, the human study results showed that the value of 
hepatic fat quantification of DECT with MMD has good agreement with that 
of histologic examination as a reference standard and that of MRI as a 
technical standard. For that reason, the equation regarding the HFF values of 
the MMD of precontrast DECT and the pathology results, both of which were 
obtained in the animal study, did not work in the human study. This difference 
would be due to the difference of the evaluation method and the protocol, and 
above all, the fat accumulation pattern in the rabbit liver which was mainly 
microvesicular hepatic steatosis rather than the macrovesicular pattern usually 
observed in human hepatic steatosis. Considering that the fat fractions of 
DECT with MMD and MR IDEAL IQ did not differ significantly (P = 0.061 - 
0.266) in the animal experiment, the imaging modalities, such as CT and MRI, 
might not completely reflect the microvesicular steatosis on the fat-fraction 
map. Actually, considering some previous studies (51-54) which reported that 
the visual histologic fat fraction was two or three times higher than the fat 




is encouraging that the mean differences of Bland-Altman plots comparing the 
fat fractions of DECT with MMD, MR IDEAL, and the pathology results did 
not differ significantly from zero in this human study.  
The LFQ algorithm used in this study uses fat, liver tissue, and blood in the 
material basis and also considers iodinated contrast media by applying the 
VUE image in the case of post-contrast DECT images. However, regarding 
the fat fraction of post-contrast DECT with MD in this animal study, rather 
than MMD, the results were negative values, and which is impossible in the 
real world. This is the limitation of the MD which considers only two material 
bases of fat and soft tissue. Actually, the composition of human organs and 
tissues is too complex for two-material decomposition to make an accurate 
material-specific image with only two materials in the material basis. It is said 
that addressing this problem was the motivation for the development of the 
MMD (37-39).  
This study has some limitations. First, the numbers of study subjects in the 
hepatic steatosis severity groups and the control group were relatively small. 
In addition, the moderate degree of hepatic steatosis was not well-established 
in this animal experiment, and there was also only two moderate degrees of 
hepatic steatosis and no severe degree of hepatic steatosis in this human study. 
Next, the iron overloaded animal model with hepatic steatosis was not used 
for the accuracy evaluation of DECT with MMD in the quantification of HFF. 
There may be some methods to create an iron overload in animal experiments, 
such as a high iron diet for several to 12 months (55-57), intravenous or 




59), or injection of an iron oxide MR contrast agent or intravenous iron 
supplement at the time of the imaging study. However, these methods were 
not feasible in this study. Last, this human study did not evaluate the accuracy 
of DECT with MMD in the situation of the presence of iron or iodinated 
contrast media and did not record the presence of the iron on the pathologic 
results. Therefore, further studies are needed to assess the accuracy of DECT 
with MMD in HFF quantification in the presence of iron.  
In conclusion, the quantification of HFF using DECT with MMD is well-
correlated and shows good agreement with the histologic and MRI fat 
fractions even in the presence of iodinated contrast media and they have 
comparable sensitivity and specificity to the histology and MRI. 
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서론: 이중에너지 전산화 단층촬영 (DECT)과 다물질 분해 방법 
(MMD)을 이용한 간 내 지방분율 정량화에 있어, 조직학적 결과 및 
자기공명영상을 표준으로 삼아 그 정확성과 실현 가능성을 평가하
며, 조영전 전산화 단층촬영과 비교한 진단능을 평가하고자 한다. 
 
방법: 본 연구는 소속 기관의 동물실험윤리위원회와 연구윤리심의위
원회의 승인을 받았다. 동물연구를 위해 16 마리의 토끼를 4 군으로 
나누고, 고지방, 고콜레스테롤 사료를 각각 0, 2, 4, 6 주 동안 식이 
시켜 다양한 정도의 지방간을 유발시켰다. 6 주 경과 후에 조영전 
단일에너지 전산화 단층촬영(SECT)과 다중촬영 DECT 를 시행하
고, MMD 를 이용하여 DECT 자료에서부터 간 지방분율 영상을 얻
었다. 같은 날 화학이동 자기공명영상(MRI)과 간 조직학적 검사를 
시행하였다. MRI 와 조직학적 검사를 통하여 간의 지방분율을 측정
하였다. 사람연구를 위해 14 명의 생체간이식 공여자와 11 명의 간
이식 수여자를 모집하였고, 이들은 조영전 DECT 와 MRI, 및 수술
을 시행받았다. CT 감쇄 값을 CT 영상에서 측정하고, DECT 로부
터 얻은 지방분율 영상과 MRI 에서 간의 지방분율을 측정하고, 간 
조직 검체에서 조직학적 지방 축적 정도를 평가하였다. DECT 에서 




상관관계및 일치도를 분석하고, 진단능으로 민감도와 특이도를 평가
하였다 
 
결과: 조직학적 간 지방분율은 조영전 영상의 CT 감쇄 값과는 강한 
음의 선형 상관관계를 보였다. 동물연구에서, DECT 에서 얻은 간 
지방분율은 MRI 및 조직학적으로 구한 간지방분율과 강한 상관관
계를 보였으며, 요오드를 함유하고 있는 조영제가 있음에도 불구하
고 다중촬영 DECT 에서 얻은 간지방분율 값에는 큰 차이가 없었다. 
하지만 DECT 에서 얻은 간 지방분율 값과 MRI 및 조직학적으로 
구한 간지방분율 값의 일치도는 좋지 않았다. 사람연구에서는, 비록 
DECT 에서 얻은 간 지방분율 값과 MRI 및 조직학적으로 구한 간
지방분율 값 사이에 상관관계는 없었으나, 그 값들 사이에 높은 일
치도를 나타내었다. DECT 의 간 지방분율 진단에 대한 민감도와 특
이도는 조영전 전산화 단층촬영 및 자기공명영상의 결과와 비견할
만하였다 (P = 0.17–0.82).  
 
결론: 이중에너지 전산화 단층촬영과 다물질 분해 방법을 이용한 간 
내 지방분율 정량화는 요오드를 함유한 조영제가 있는 경우에도 조
직학적 및 자기공명영상의 간 지방분율과 강한 상관관계와 높은 일
치도를 보이며, 조영전 전산화 단층촬영과 자기공명영상과 비교할만





주요어 : 이중에너지 전산화 단층촬영; 다물질 분해 방법; 간 내 지
방분율 정량화; 토끼 지방간 
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